This article is more than 5 years old. Information may no longer be current.
Staging system, response evaluation criteria anticipate survival in retinoblastoma patients
Click Here to Manage Email Alerts
A proposed staging system and response evaluation criteria helped to predict event-free-survival and overall survival at baseline and after neoadjuvant chemotherapy in advanced retinoblastoma.
The study included 28 patients with stage 3 retinoblastoma who underwent MRI at baseline and after three rounds of chemotherapy preceding enucleation.
The staging system was based on optic nerve thickening, extent of involvement on MRI and contrast enhancement features. The response evaluation criteria were based on the optic nerve staging and reduction in tumor size on MRI after chemotherapy.
Study results showed event-free-survival was anticipated by the staging system at baseline (P = .005) and after chemotherapy (P < .001). Overall survival also was predicted by the staging system at baseline (P = .002) and after chemotherapy (P = .001).
The response evaluation criteria indicated significantly better event-free-survival (P < .001) and overall survival (P = .024) in patients with complete or partial response after chemotherapy than in patients with stable or progressive disease.
Click Here to Manage Email Alerts